Glycoprotein News and Research

RSS

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

A new paper discusses an intriguing new mechanism of immune evasion traceable to specific mutations in the B.1.427/B.1.429 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2021

Research shows how loss of de-N-glycosylation enzyme causes detrimental effects

Peptide: N-glycanase (NGLY1) is an evolutionarily conserved enzyme for removing N-linked glycans (N-glycans) from glycoproteins and is involved in proteostasis of N-glycoproteins in the cytosol. In 2012, a rare genetic disorder called NGLY1 deficiency was discovered by an exome analysis.

7 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

Mutations in the Epsilon variant contribute to SARS-CoV-2 immune evasion

Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

6 Jul 2021

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

A recent tour-de-force study by researchers from the United Kingdom reveals variants of the human angiotensin-converting enzyme 2 (ACE2) that can improve or decrease binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – including two variants with distinct population distributions showing an enhanced affinity for viral spike glycoprotein.

5 Jul 2021

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

A compelling report, recently released on the bioRxiv* preprint server, describes unexpectedly powerful inhibition of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by thiol-based mucolytic compounds P2119 and P2165, by preventing the virus spike from binding to its host cell receptor, the angiotensin-converting enzyme 2 (ACE2).

5 Jul 2021

Varenicline blocks SARS-CoV-2 infection in cells and animal models

A new paper released on the bioRxiv* preprint server suggests that the nicotinic acetylcholine receptor (nACHR) agonist, varenicline tartrate, has antiviral activity against the virus.

5 Jul 2021

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

The antibodies are capable of neutralizing a wide range of SARS-CoV-2 variants even at sub-nanomolar concentrations. In addition, the combinations of these antibodies reduce the risk of generating escape mutants in vitro. The study is published in the journal Science.

5 Jul 2021

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.

5 Jul 2021

Grapevine leaf extract inhibits SARS-CoV-2 and HSV-1 replication in the lab

Researchers in Italy have shown that leaf extract from the common grapevine – Vitis vinifera – exhibits significant antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

1 Jul 2021

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

In a recently published article scientists have provided a detailed description of the utility of mannose-specific lectins in preventing coronavirus infections. They have specifically explained how mannose-specific lectins derived from plants, algae, fungi, and bacteria selectively bind N-glycans present on the surface of viral spike protein and how such interactions can be medically utilized to control coronavirus transmission.

1 Jul 2021

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

A recent Diagnostics study discusses the specific antibody response that occurred in individuals after they had received the SARS-CoV-2 vaccine.

1 Jul 2021

Study highlights changes within SARS-CoV-2 variants that could be exploited to design effective inhibitors

A computational study that analyzes and explores the time-based structures of the SARS-CoV-2 variants with specific spike (S) protein mutations is discussed here.

30 Jun 2021

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.

29 Jun 2021

Study explores structure, activity, and inhibition of TMPRSS2 implicated in SARS-CoV-2 activation

Researchers from Canada recently presented an efficient strategy for recombinant production of enzymatically active TMPRSS2 ectodomain, enabling enzymatic characterization and the 1.95 Å X-ray crystal structure. Their work is published on the bioRxiv* preprint server while awaiting peer-review.

29 Jun 2021

Could microalgae-derived antiviral compounds combat SARS-CoV-2 and other viruses?

A new review article published in the journal Antibiotics reports the presence of a large number of bioactive compounds in microalgae that target chemical structures present only in their structure.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

SARS-CoV-2 causes ER-stress-activated unfolded protein response leading to cell death

A new study describes the varying ways in which the virus co-opts the machinery of the host cell following infection to evade or modulate the host immune response, alter the pattern of translation of viral proteins, and the release of new viral particles.

24 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

The effect of novel insertion mutation in SARS-CoV-2 spike glycoprotein RNA

In a recent study, a group of researchers discuss the functional implications of this specific S protein mutation on SARS-CoV-2.

22 Jun 2021

Glycoprotein News and Research

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

Research shows how loss of de-N-glycosylation enzyme causes detrimental effects

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

Mutations in the Epsilon variant contribute to SARS-CoV-2 immune evasion

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

Varenicline blocks SARS-CoV-2 infection in cells and animal models

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

Grapevine leaf extract inhibits SARS-CoV-2 and HSV-1 replication in the lab

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

Study highlights changes within SARS-CoV-2 variants that could be exploited to design effective inhibitors

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Study explores structure, activity, and inhibition of TMPRSS2 implicated in SARS-CoV-2 activation

Could microalgae-derived antiviral compounds combat SARS-CoV-2 and other viruses?

Why SARS-CoV-2 delta variant is more infectious

SARS-CoV-2 causes ER-stress-activated unfolded protein response leading to cell death

Researchers review the origins of SARS-CoV-2 and present treatment methods

The effect of novel insertion mutation in SARS-CoV-2 spike glycoprotein RNA

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News